DrugPatentWatch Database Preview
Heron Theraps Inc Company Profile
What is the competitive landscape for HERON THERAPS INC, and when can generic versions of HERON THERAPS INC drugs launch?
There are eight US patents protecting HERON THERAPS INC drugs.
There are twenty-one patent family members on HERON THERAPS INC drugs in ten countries and seven supplementary protection certificates in four countries.
Summary for Heron Theraps Inc
International Patents: | 21 |
US Patents: | 8 |
Tradenames: | 2 |
Ingredients: | 2 |
NDAs: | 2 |
Drugs and US Patents for Heron Theraps Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Heron Theraps Inc | SUSTOL | granisetron | INJECTION, EXTENDED RELEASE;SUBCUTANEOUS | 022445-001 | Aug 9, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | |||||
Heron Theraps Inc | CINVANTI | aprepitant | EMULSION;IV (INFUSION) | 209296-001 | Nov 9, 2017 | RX | Yes | Yes | 9,561,229 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
Heron Theraps Inc | SUSTOL | granisetron | INJECTION, EXTENDED RELEASE;SUBCUTANEOUS | 022445-001 | Aug 9, 2016 | RX | Yes | Yes | 8,252,304 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
Heron Theraps Inc | SUSTOL | granisetron | INJECTION, EXTENDED RELEASE;SUBCUTANEOUS | 022445-001 | Aug 9, 2016 | RX | Yes | Yes | 6,613,355 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for Heron Theraps Inc
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
6,861,068 | Pharmaceutical compositions using semi-solid delivery vehicle | ➤ Try a Free Trial |
8,252,306 | Process for preparing a semi-solid delivery vehicle comprising granisetron | ➤ Try a Free Trial |
Patent No. | Title | Estimated Patent Expiration |
International Patents for Heron Theraps Inc Drugs
Country | Document Number | Estimated Expiration |
---|---|---|
Canada | 2579297 | ➤ Try a Free Trial |
Spain | 2529574 | ➤ Try a Free Trial |
Japan | 2017008113 | ➤ Try a Free Trial |
Spain | 2529574 | ➤ Try a Free Trial |
Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Heron Theraps Inc Drugs
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
2004002 | Lithuania | ➤ Try a Free Trial | PRODCUT NAME: 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(TRIFLUORMETIL)FENIL]ETOKSI]-3-(4-FLUORFENIL)-4-MORFOLINIL]METIL]-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO./DATE: EU/1/03/262/001-006/20031111 |
C0019 | France | ➤ Try a Free Trial | PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111 |
C/GB08/021 | United Kingdom | ➤ Try a Free Trial | PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111 |
C0010 | France | ➤ Try a Free Trial | PRODUCT NAME: APREPITANT; REGISTRATION NO/DATE: EU/1/03/262/001 20031111 |
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.